enVVeno Medical Corporation - NVNO STOCK NEWS

Welcome to our dedicated page for enVVeno Medical Corporation news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on enVVeno Medical Corporation stock.

enVVeno Medical Corporation (NASDAQ:NVNO), based in Irvine, California, is a late-stage clinical medical device company dedicated to developing innovative bioprosthetic (tissue-based) solutions for treating venous disease. The company's flagship product, the VenoValve®, is a first-in-class surgical replacement venous valve designed to treat severe deep venous Chronic Venous Insufficiency (CVI). CVI occurs when leg vein valves fail, leading to blood reflux, pooling, venous hypertension, severe pain, leg swelling, and recurrent ulcers.

The VenoValve is currently undergoing evaluation in the SAVVE U.S. pivotal study, where it has shown promising results, with 97% of patients demonstrating clinical improvement and 74% achieving a clinically meaningful benefit after six months. The company plans to file for FDA pre-market approval in Q4 2024. Additionally, enVVeno is developing the enVVe™, a non-surgical, transcatheter-based replacement venous valve, expected to enter pivotal trials in Q4 of 2024.

In recent updates, enVVeno presented positive preliminary safety data from the SAVVE study at the 50th Annual VEITH Symposium and shared encouraging topline efficacy data at the American Venous Forum and Charing Cross International Symposium. Financially, the company reported ending the first quarter of 2024 with $42.9 million in cash and investments, sufficient to fund operations through 2025.

enVVeno's mission is to address the unmet needs of approximately 2.5 million new CVI patients annually in the U.S. with no effective current treatments. For more information on their groundbreaking products, visit enVVeno.com.